Dr. Bette L Gould, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 210 Main St, 100, Half Moon Bay, CA 94019 Phone: 650-712-1234 Fax: 650-726-5749 |
Pearl Lynn Yee, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 210 Main St, Suite 100, Half Moon Bay, CA 94019 Phone: 650-712-1234 |
Dr. Neda Moshasha, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 80 Cabrillo Hwy N, Suite J, Half Moon Bay, CA 94019 Phone: 650-726-3937 |
Hmb Optometry Family Eye Care Optometrist Medicare: Medicare Enrolled Practice Location: 80 Cabrillo Hwy N, Suite J, Half Moon Bay, CA 94019 Phone: 650-726-3937 |
Hmb Optometric Group Llc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 80 Cabrillo Hwy N, Suite J, Half Moon Bay, CA 94019 Phone: 650-726-3937 |
Veronica Lam, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 210 Main St Ste 100, Half Moon Bay, CA 94019 Phone: 650-712-1234 Fax: 650-726-5749 |
News Archive
The coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into a global pandemic destroying lives and economies. COVID-19 is not curable, so vaccines are the only safeguard during this pandemic.
Tragic miscarriages for a couple have led to a discovery with potentially broad implications for future disease treatments, according to a team of researchers at the University of North Carolina School of Medicine. They identified a previously undiscovered gene mutation underlying hydrops fetalis – a fatal condition to fetuses due to fluid buildup in the space between organs.
VIVUS, Inc. today announced that on August 31, 2011, during the late breaking poster session at the 29th International Epilepsy Congress in Rome, Italy, Dr. Alison Pack, Associate Professor of Clinical Neurology, Department of Neurology, Columbia University Medical Center, will present the results of a retrospective study of medical claims data on oral clefts (OC) and major congenital malformations (MCMs) associated with in utero topiramate exposure.
A new targeted therapy for prostate cancer halts tumor growth in animals with advanced prostate cancer that is resistant to hormone therapy, a new study finds. The results will be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston.
› Verified 6 days ago